Class I Phosphatidylinositol 3-Kinases
-
Subject Areas on Research
-
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
-
ARID1A-mutated ovarian cancers depend on HDAC6 activity.
-
Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer.
-
Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.
-
Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.
-
Comprehensive molecular portraits of human breast tumours.
-
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
-
Effect of cyclical intermittent hypoxia on Ad5CMVCre induced solitary lung cancer progression and spontaneous metastases in the KrasG12D+; p53fl/fl; myristolated p110fl/fl ROSA-gfp mouse.
-
Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels.
-
Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer.
-
Genetic heterogeneity of diffuse large B-cell lymphoma.
-
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
-
Leukaemia hijacks a neural mechanism to invade the central nervous system.
-
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA.
-
Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
-
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.
-
Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
-
PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
-
PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism.
-
PIK3CA mutation in a mixed dysembryoplastic neuroepithelial tumor and rosette forming glioneuronal tumor, a case report and literature review.
-
PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.
-
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
-
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
-
Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer.
-
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
-
Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism.
-
Restoration of beta-adrenergic receptor signaling and contractile function in heart failure by disruption of the betaARK1/phosphoinositide 3-kinase complex.
-
Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
-
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
-
Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies.
-
The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.